Seven institutions across three continents will evaluate the company’s Photonova Spectra CT system, examining image quality, radiation dose, workflow efficiency, and potential clinical applications.
GE HealthCare is expanding its global clinical and research collaborations for Photonova Spectra, its next-generation photon-counting CT system. Seven academic hospitals and research institutions in North America, Europe, and Asia are taking part.
The structured evaluations follow the system’s CE Mark, US FDA 510(k) clearance, and approval from Japan’s Pharmaceuticals and Medical Devices Agency. The institutions will assess image quality, spectral performance, workflow efficiency, and diagnostic utility. They will also explore quantitative imaging and material characterization.
Photonova Spectra uses GE HealthCare’s proprietary Deep Silicon detector technology. According to the company, the system is designed to deliver ultra-high-definition and spectral imaging through a one-scan, universal workflow. GE HealthCare says this combination of high spatial resolution and material characterization may support quantitative imaging, tissue characterization, spectral biomarker research, and simplified imaging protocols.
“Deep Silicon photon-counting CT has the potential to change not only what clinicians can see, but what they can understand from every scan—creating new possibilities for early detection, personalized care and diagnostic confidence,” says Chad Rowland, executive director of global CT at GE HealthCare, in a release. “Realizing that potential requires close collaboration with the research and clinical community.”
New and Expanded Collaborations
Three institutions are new to the network, and two are renewing or broadening existing work with GE HealthCare.
Keio University Hospital (Tokyo)—Researchers will explore quantitative and spectral imaging techniques and emerging clinical applications across future clinical and research use cases.
Centro Cardiologico Monzino IRCCS (Milan, Italy)—Investigators will assess the system in cardiovascular imaging, including quantitative assessment, tissue characterization, and workflow considerations.
“Cardiovascular disease remains one of the world’s leading health challenges, underscoring the need for imaging technologies that enable more informed clinical decision-making,” says Gianluca Pontone, professor and deputy scientific director at Centro Cardiologico Monzino IRCCS, in a release.
Universitätsspital Zürich (Zürich, Switzerland)—A team from the department of nuclear medicine will evaluate Photonova Spectra for coronary CT angiography. The team will focus on optimizing radiation dose while maintaining diagnostic performance.
“We aim to determine how best to translate these capabilities into robust, dose-efficient CCTA protocols that support confident clinical decision-making,” says Philipp Kaufmann, professor and director of the Department of Nuclear Medicine at Universitätsspital Zürich, in a release.
University of Wisconsin–Madison—Researchers have renewed their collaboration with GE HealthCare. They will build on earlier investigations of the photon-counting CT system, examining imaging protocols, quantitative performance, and technical measures of image quality.
Stanford Medicine (Palo Alto, California)—The multidisciplinary team has expanded its collaboration and broadened its scope of technical and human-subject studies. Those studies cover reconstruction methods, image presentation workflows, and disease-specific applications. The applications include ultra-high-resolution structural visualization, tissue characterization, and potential new imaging biomarkers.
“We’re excited to continue our work with Photonova Spectra, building on our experience in reconstruction, image analysis and human-subject research to further investigate the capabilities of photon-counting CT and where it may create new opportunities for clinical practice and scientific discovery,” says Adam Wang, PhD, assistant professor in the Department of Radiology and electrical engineering at Stanford University, in a release.
Collaborations Established After CE Mark
Two other institutions began working with GE HealthCare after the system received its CE Mark.
- UZ Brussel – Vrije Universiteit Brussel (Brussels, Belgium): The team is evaluating advanced cardiac imaging capabilities, including coronary assessment and functional analysis. It is also generating clinical evidence and refining imaging protocols for routine cardiovascular care.
- Rigshospitalet (Copenhagen, Denmark): Researchers are investigating broad clinical applications, including pediatric and low-dose imaging, tissue characterization, and the use of spectral information in complex clinical cases.
GE HealthCare says its engineers, scientists, and product specialists will work alongside the collaborating institutions to translate scientific evidence and real-world clinical experience into future product enhancements.
Photo caption: Photonova Spectra
Photo credit: GE HealthCare